Weekly report on investment and financing in the field of health care (November 8-November 14): Shaxi Pharmaceutical was acquired by Jingxin Pharmaceutical Co., Ltd.

億歐網 · Nov 15, 2021 09:00

据亿欧数据统计，上周（2021年11月8日-2021年11月14日）共披露404起投融资事件，涉及161家国内企业，243家国外企业，融资总额约2642.16亿元。

其中，医疗健康领域共披露56起投融资事件，涉及27家国内企业，29家国外企业，融资总额约157.34亿元。

国内医疗健康领域共有2家企业被并购，25家企业获投，融资总额约49.83亿元。

1.沙溪制药被京新药业并购，前者总部位于中国广东省，是一家中成药和化学药品生产商；

2.吉芮医疗被可孚医疗并购，前者总部位于中国上海市，是一家电动轮椅及老年代步车研发商；

3.胡庆余堂获得2.1亿人民币战略投资，投资方为京新药业，本轮融资金额在本年度所有战略投资中排名前50%。胡庆余堂总部位于中国浙江省，是一家中药加工生产商；

4.东蕴医疗获得1000万美元战略投资，投资方为益世科，本轮融资金额在本年度所有战略投资中排名前50%。东蕴医疗总部位于中国上海市，是一家辅助生殖领域医疗器械研发商；

5.小荷医疗器械获得战略投资，投资方为字节跳动，该公司总部位于中国海南省，是一家医疗器械服务商；

6.兰丁高科完成3.2亿人民币D轮融资，投资方为阿里健康、以太投资，该公司总部位于中国湖北省，是一家宫颈癌筛查病理检测分析仪；

7.菲森科技完成D轮融资，投资方为泰康投资，该公司总部位于中国广东省，是一家口腔医学影像设备研发商；

8.牙医管家完成D轮融资，投资方为泰康资产，该公司总部位于中国广东省，是一家口腔诊所管理服务平台；

9.裕策生物完成数千万人民币C+轮融资，投资方为繸子财富，该公司总部位于中国广东省，是一家肿瘤精准免疫治疗基因检测和大数据分析平台；

10.健海科技完成5亿人民币B+轮融资，投资方为红杉中国、华兴新经济基金、三正健康，本轮融资金额在本年度所有B+轮融资中排名前5%。健海科技总部位于中国浙江省，是一家患者院后管理平台；

11.长木谷完成5.4亿人民币B轮融资，投资方为鼎晖投资、IDG资本、中金资本、中发展启航投资、元生创投，本轮融资金额在本年度所有B轮融资中排名前20%。长木谷总部位于中国北京市，是一家骨科人工智能解决方案提供商；

12.挚盟医药完成3.5亿人民币B轮融资，投资方为紫曜基金、达晨财智、尚珹资本、基石资本、达武创投、德屹资本，本轮融资金额在本年度所有B轮融资中排名前50%。挚盟医药总部位于中国上海市，是一家慢性肝病治疗药物研发商；

13.新格元完成数千万美元B轮融资，投资方为3w Global Investment、夏尔巴投资、鼎晖投资、和玉资本、超弦基金、清池资本、礼来亚洲基金、ARCH、晨岭资本、晨壹投资、软银中国资本，该公司总部位于中国江苏省，是一家分子诊断试剂和设备生产商；

14.苏州仁东医学完成数亿人民币B轮融资，投资方为政府基金，该公司总部位于中国江苏省，是一家基因大数据及基因检测服务提供商；

15.微米生物完成数亿人民币B轮融资，投资方为佳鸿医疗、创钰投资、幂方资本、中金资本，该公司总部位于中国广东省，是一家诊断试剂研发商；

16.铨融医药完成数千万人民币B轮融资，投资方为楹联健康基金、惠每资本，该公司总部位于中国上海市，是一家临床试验信息化服务商；

17.MingSight完成2000万美元Pre-B轮融资，投资方为凯泰资本，本轮融资金额在本年度所有Pre-B轮融资中排名前20%。MingSight总部位于中国广东省，是一家眼科医疗药物研发商；

18.翼思生物完成1.8亿美元A轮融资，投资方为高盛、WTT investment、KB Investment、HBM Healthcare Investments、通和毓承、Mubadala、Ruentex Group，本轮融资金额在本年度所有A轮融资中排名前1%。翼思生物总部位于中国上海市，是一家中枢神经药物生产商；

19.正序生物完成3亿人民币A轮融资，投资方为博裕投资、礼来亚洲基金、泰福资本、红杉中国、万物资本、联新资本，本轮融资金额在本年度所有A轮融资中排名前10%。正序生物总部位于中国上海市，是一家遗传性疾病免疫治疗平台；

20.微创神通完成3126万美元A轮融资，投资方为贝霖资本、博华资本，本轮融资金额在本年度所有A轮融资中排名前20%。微创神通总部位于中国上海市，是一家中枢神经系统疾病治疗器械研发商；

21.逗点生物完成数亿人民币A轮融资，投资方为元生创投、深创投、深圳高新投、软银中国资本，本轮融资金额在本年度所有A轮融资中排名前50%。逗点生物总部位于中国广东省，是一家样本处理及检测解决方案提供商；

22.科镁联完成1860万美元Pre-A轮融资，投资方为联想之星、博远资本、汇鼎投资，本轮融资金额在本年度所有Pre-A轮融资中排名前5%。科镁联总部位于中国上海市，是一家新型寡核苷酸药物开发商；

23.标新生物完成数亿人民币Pre-A轮融资，投资方为约印医疗基金、倚锋创业投资、沂景投资，本轮融资金额在本年度所有Pre-A轮融资中排名前5%。标新生物总部位于中国上海市，是一家医药科技研发平台；

24.未名拾光完成5000万人民币Pre-A轮融资，投资方为弘毅创投、真格基金、嘉程资本，本轮融资金额在本年度所有Pre-A轮融资中排名前20%。未名拾光总部位于中国北京市，是一家医美护肤品研发商；

25.女娲生命完成Pre-A轮融资，投资方为金晟资本、觉资投资，该公司总部位于中国广东省，是一家辅助生殖技术研发商；

26.拜锐生物完成数千万人民币天使轮融资，投资方为宁波市天使投资引导基金、领衔健康基金，本轮融资金额在本年度所有天使轮融资中排名前50%。拜锐生物总部位于中国浙江省，是一家生物材料研发商；

27.人良生物完成1000万人民币天使轮融资，投资方为迁鲸科技、隽泰投资，该公司总部位于中国上海市，是一家聚葡萄糖及膳食纤维产品产销商。

国外医疗健康领域共有1家企业上市，4家企业被并购，24家企业获投，融资总额约107.51亿元。

1.Vaxxinity上市，该公司总部位于美国，是一家美国生物技术公司；

2.Ivantis被爱尔康并购，前者总部位于美国，是一家美国微创青光眼手术服务供应商；

3.Diopsys被LumiThera并购，前者总部位于美国，是一家美国医疗器械公司；

4.Cardiologs被飞利浦并购，前者总部位于法国，是一家法国心电图分析系统研发商；

5.视光师验眼中心被希玛眼科并购，前者是一家视力验光服务提供商；

6.Autolus获得2.5亿美元战略投资，投资方为黑石，本轮融资金额在本年度所有战略投资中排名前10%。Autolus总部位于英国，是一家英国细胞治疗服务提供商；

7.Gyroscope Therapeutics获得6000万美元战略投资，投资方为Sanofi，本轮融资金额在本年度所有战略投资中排名前20%。Gyroscope Therapeutics总部位于英国，是一家英国眼科疾病治疗服务商；

8.PierianDx获得4750万美元战略投资，投资方为奥博资本OrbiMed、SJF Ventures、Catalyst Health Ventures、ATW Partners、Research Triangle Institute、Inova Health Systems，本轮融资金额在本年度所有战略投资中排名前20%。PierianDx总部位于美国，是一家美国临床基因组学解决方案提供商；

9.B-Secur获得1187万美元战略投资，投资方为Bank of Ireland、First Capital Ventures，本轮融资金额在本年度所有战略投资中排名前50%。B-Secur总部位于英国，是一家英国健康监测平台；

10.HealthSnap获得500万美元战略投资，投资方为MacDonald Ventures、Florida Funders、OPKO Health、Hard Facts、W-5 Group、6nine26，该公司总部位于美国，是一家美国慢性病管理服务商；

11.MyLife Technologies获得400万美元战略投资，投资方为Fare Capital、SAL Beheer，该公司总部位于荷兰，是一家荷兰疫苗接种技术提供商；

12.Antegenes获得57万美元战略投资，该公司总部位于爱沙尼亚，是一家爱沙尼亚新型基因检测服务商；

13.Biond Biologics完成1500万美元C轮融资，投资方为Harel、Deep Insight、Heritage Group，该公司总部位于以色列，是一家以色列免疫疗法研发商；

14.Arbor Biotechnologies完成2.15亿美元B轮融资，本轮融资金额在本年度所有B轮融资中排名前5%。Arbor Biotechnologies是一家基因编辑疗法研发商；

15.Acrivon完成1亿美元B轮融资，投资方为Surveyor Capital、Chione、HBM Healthcare Investments AG、Pureos Bioventures、Marshall Wace、Perceptive Advisors、HealthCor Partners、RA Capital Management、Sands Capital Ventures、Wellington，本轮融资金额在本年度所有B轮融资中排名前10%。Acrivon总部位于美国，是一家美国肿瘤治疗服务提供商；

16.Infinitus Systems完成3000万美元B轮融资，投资方为谷歌风投、KPCB、Coatue，本轮融资金额在本年度所有B轮融资中排名前50%。Infinitus Systems总部位于美国，是一家美国医疗语音机器人研发商；

17.GeneCentric Therapeutics完成750万美元B轮融资，投资方为Hatteras Venture Partners、IAG Capital Partners、LabCorp、Alexandria Venture Investments（AVI），该公司总部位于美国，是一家美国癌症治疗药物研发商；

18.Microport NeuroTech完成1.5亿美元A轮融资，投资方为BVF、HHF Capital、中金公司，本轮融资金额在本年度所有A轮融资中排名前5%。Microport NeuroTech总部位于开曼群岛，是一家神经血管疾病治疗及医疗器械研发制造商；

19.GlycoEra完成4900万美元A轮融资，投资方为Sofinnova Partners、5AM Ventures、Roche Venture Fund、LimmaTech Biologics，本轮融资金额在本年度所有A轮融资中排名前10%。GlycoEra总部位于瑞士，是一家瑞士新型生物制剂研发商；

20.Nitrase Therapeutics完成4500万美元A轮融资，投资方为Sofinnova Partners、Bristol-Myers Squibb、AbbVie Biotech Ventures、Mission Bay Capital、Alexandria Venture Investments（AVI），本轮融资金额在本年度所有A轮融资中排名前10%。Nitrase Therapeutics是一家帕金森病治疗药物研发商；

21.DeepCure完成4000万美元A轮融资，投资方为TLV Partners、Sapir Venture Partners、Benon Group、Morningside Ventures，本轮融资金额在本年度所有A轮融资中排名前10%。DeepCure总部位于美国，是一家美国AI药物研发商；

22.Mosaic Wellness完成2400万美元A轮融资，投资方为Matrix Partners、Sequoia Capital India、Elevation Capital，本轮融资金额在本年度所有A轮融资中排名前20%。Mosaic Wellness总部位于印度，是一家印度保健产品研发生产商；

23.Signos完成1300万美元A轮融资，投资方为GV，本轮融资金额在本年度所有A轮融资中排名前50%。Signos总部位于美国，是一家美国体重管理服务提供商；

24.BioSapien完成205.6万美元Pre-A轮融资，投资方为JPIN Venture Catalysts、Cedas Foundation、Side Door Ventures、SOSV、George and Saul、Hikma Ventures、Microventures、Infinite Capital，该公司总部位于美国，是一家抗癌药物研发商；

25.Orthogon Therapeutics完成800万美元天使轮融资，本轮融资金额在本年度所有天使轮融资中排名前10%。Orthogon Therapeutics是一家抗病毒药物和抗感染疗法药物开发公司；

26.Asgard Therapeutics完成696万美元种子轮融资，投资方为Novo Holdings、勃林格殷格翰风险基金、Industrifonden，本轮融资金额在本年度所有种子轮融资中排名前20%。Asgard Therapeutics总部位于瑞典，是一家瑞典生物技术公司；

27.Lindus Health完成500万美元种子轮融资，投资方为Hambro Perks、CalmStorm Venture、Presight Capital、个人投资人、Amino Collective、Seedcamp、Firstminute Capital，本轮融资金额在本年度所有种子轮融资中排名前20%。Lindus Health总部位于英国，是一家英国临床实验服务商；

28.Videra Health完成300万美元种子轮融资，投资方为OATV、个人投资人、Rose Park、Peterson Ventures，本轮融资金额在本年度所有种子轮融资中排名前50%。Videra Health总部位于美国，是一家美国医疗保健服务；

29.Acendian完成种子轮融资，投资方为U.S. Small Business Administration，该公司总部位于美国，是一家美国药品生产采购商。

截至2021年11月14日，全球医疗健康领域本年度共发生2105起投融资事件，总融资金额约9454.48亿元。国内医疗健康领域本年度共发生1092起投融资事件，总融资金额约2534.15亿元。

注：

1.医疗健康领域指的是亿欧数据行业分类中的医疗健康这1个行业。

2.上述融资金额统计，模糊金融及未披露金额已根据一定规则转化成估算数值，并统一换算为人民币。

回顾11月1日-11月7日医疗健康领域投融资情况，请点击医疗健康领域投融资周报（11月1日-11月7日）：三叶草生物制药上市

亿欧数据致力于为能引领科技与产业发展的组织，提供好用的行业洞察工具，有效的商业决策工具。想要了解更多领域的详细投融资数据，欢迎访问亿欧数据。

According to Euro data, a total of 404 investment and financing events were disclosed last week (November 8, 2021-November 14, 2021), involving 161 domestic enterprises and 243 foreign enterprises, with a total financing of about 264.216 billion yuan.

Among them, the medical and health sector disclosed a total of 56 investment and financing events, involving 27 domestic enterprises and 29 foreign enterprises, with a total financing of about 15.734 billion yuan.

In the field of medical and health care in China, a total of 2 enterprises were acquired and 25 enterprises were invested, with a total financing of about 4.983 billion yuan.

1. Shaxi Pharmaceutical was acquired by Jingxin Pharmaceutical, a manufacturer of proprietary Chinese medicines and chemicals headquartered in Guangdong Province, China.

2. Geerui Medical was acquired by Kefu Medical, the former headquartered in Shanghai, China, is a developer of electric wheelchairs and scooters for the elderly.

3. Hu Qingyutang received 210 million yuan in strategic investment from Jingxin Pharmaceutical Co., Ltd., and this round of financing ranks in the top 50% of all strategic investments this year. Hu Qingyutang, headquartered in Zhejiang Province, China, is a traditional Chinese medicine processing manufacturer.

4. Dongyun Medical has received a strategic investment of US $10 million, invested by Yishike, and the amount of financing this round ranks in the top 50% of all strategic investments this year. Dongyun Medical, headquartered in Shanghai, China, is a medical device developer in the field of assisted reproduction.

5. Xiaohe medical device obtains strategic investment, and the investor is byte-beating. The company, headquartered in Hainan Province, China, is a medical device service provider.

6. Landing Hi-Tech completed 320 million RMB D-round financing, invested by Alibaba Health Information Technology and Ethernet Investment. the company, headquartered in Hubei Province, China, is a pathological analyzer for cervical cancer screening.

7. Feisen Technology has completed D-round financing, with Taikang Investment as the investor. the company is headquartered in Guangdong Province, China, and is a developer of stomatology imaging equipment.

8. Dental butler D-round completed financing, the investor is Taikang assets, the company is headquartered in Guangdong Province, China, is a dental clinic management service platform

9. Yutze Biological has completed tens of millions of RMB C+ round financing, invested by Yuzi Wealth. The company, headquartered in Guangdong Province, China, is a platform for accurate gene detection and big data analysis of tumor immunotherapy.

10. Jianhai Science and Technology has completed 500 million yuan of B + round financing, invested by Sequoia Capital China, Huaxing New Economic Fund and Sanzheng Health. The amount of this round of financing ranks in the top 5% of all B + round financing this year. Jianhai Technology, headquartered in Zhejiang Province, China, is a post-hospital management platform for patients.

11. Changmu completed 540 million RMB B round financing, with investors CDH Investments, IDG Capital, CICC Capital, China Development Qihang Investment and Yuansheng Venture Capital. The current round ranks in the top 20% of all round B financing this year. Changmugu, headquartered in Beijing, China, is an orthopedic artificial intelligence solution provider.

twelve。 Zhimeng Pharmaceutical has completed 350 million RMB B round financing, with Zi Yao Fund, Dachen Caizhi, Shangyi Capital, Cornerstone Capital, Dawu Venture Capital and Deyi Capital as the investors. the amount of financing this round ranks in the top 50% of all round B financing this year. Zhimeng Pharmaceutical, headquartered in Shanghai, China, is a research and development company for the treatment of chronic liver disease.

13. Xinge yuan has completed tens of millions of dollars in round B financing with investors including 3W Global Investment, Sherpa Investment, CDH Investments, Heyu Capital, Superstring Fund, Qingchi Capital, Eli Lilly and Co Asia Fund, ARCH, Chenling Capital, Morning one Investment and Softbank Corp. China Capital. Headquartered in Jiangsu Province, China, the company is a manufacturer of molecular diagnostic reagents and equipment.

14. Suzhou Rendong Medical completed hundreds of millions of RMB B round financing, invested by government funds, the company is headquartered in Jiangsu Province, China, is a gene big data and gene testing service provider

15. Micro Biology has completed hundreds of millions of RMB B round financing, with Jiahong Medical, Chuangyu Investment, Power Capital and CICC Capital as investors. The company, headquartered in Guangdong Province, China, is a developer of diagnostic reagents.

16. Quanrong Pharmaceutical has completed tens of millions of RMB B round financing, invested by couplet Health Fund and Huimi Capital. The company, headquartered in Shanghai, China, is a clinical trial information service provider.

17.MingSight completed a $20 million Pre-B round of financing, invested by Kaitai Capital, which ranks in the top 20 per cent of all Pre-B rounds this year. MingSight, headquartered in Guangdong Province, China, is an ophthalmology medicine developer.

18. Yisi completed US $180 million in round A financing, with investors Goldman Sachs Group, WTT investment, KB Investment, HBM Healthcare Investments, Tonghe Yucheng, Mubadala and Ruentex Group. The current round ranks in the top 1 per cent of all round A financing this year. Yisi Biology, headquartered in Shanghai, China, is a manufacturer of central nervous system drugs.

19. Zhengxian completed Rmb300m A round financing, with investors from Boyu Investment, Eli Lilly and Co Asia Fund, Taifu Capital, Sequoia Capital China, WWW Capital and Lianxin Capital. The amount of financing this round ranks in the top 10% of all A round financing this year. Positive sequence biology, headquartered in Shanghai, China, is a platform for immunotherapy of hereditary diseases.

20. The Mini Chuang Avatar has completed a $31.26 million round of financing, invested by Beilin Capital and Bohua Capital, which ranks in the top 20% of all round A financing this year. Headquartered in Shanghai, China, minimally invasive Avatar is a research and development company for the treatment of central nervous system diseases.

21. Comma Bio has completed hundreds of millions of RMB A round financing, with investors including Yuansheng Venture Capital, Deep Venture Capital, Shenzhen High-tech Investment and Softbank Corp. China Capital. The amount of financing this round ranks in the top 50% of all A-round financing this year. Comma Biology, headquartered in Guangdong Province, China, is a provider of sample processing and testing solutions.

twenty-two。 Ke magnesium Union completed a $18.6 million Pre-A round of financing, with Lenovo Star, Boyuan Capital and Huiding Investment as investors. The current round ranks among the top 5 per cent of all Pre-A round financing this year. Ke magnesium Union, headquartered in Shanghai, China, is a new oligonucleotide drug developer.

23. Bioscience has completed hundreds of millions of yuan in Pre-A round financing, with investors from India Medical Fund, Yifeng Venture Capital and Yijing Investment. This round ranks among the top 5% of all Pre-A round financing this year. Bioxin Biology, headquartered in Shanghai, China, is a research and development platform for medical science and technology.

24. Weiming Siguang completed the 50 million yuan Pre-A round of financing, invested by Hony Venture Capital, ZhenFund and Jiacheng Capital, which ranks in the top 20% of all Pre-A round financing this year. Weiming Siguang, headquartered in Beijing, China, is a research and development company of medical beauty and skin care products.

25. Nuwa Life completed the Pre-A round of financing, invested by Jinsheng Capital and Jue Capital. The company, headquartered in Guangdong Province, China, is an assisted reproductive technology developer.

twenty-six。 Bairui creature has completed tens of millions of RMB angel round financing, and the investors are Ningbo angel investment guidance fund and leading health fund. This round of financing ranks in the top 50% of all angel round financing this year. Bairui Biology, headquartered in Zhejiang Province, China, is a biomaterial developer.

twenty-seven。 Renliang completed 10 million RMB angel round financing, invested by transfer Whale Technology and Juntai Investment. the company, headquartered in Shanghai, China, is a manufacturer and distributor of polyglucose and dietary fiber products.

In the field of medical and health care in foreign countries, a total of 1 enterprise has been listed, 4 enterprises have been acquired, and 24 enterprises have been invested, with a total financing amount of about 10.751 billion yuan.

1.Vaxxinity is listed, which is headquartered in the United States and is an American biotechnology company.

2.Ivantis is acquired by Alcon, a US-based provider of minimally invasive glaucoma surgery services.

3.Diopsys is acquired by LumiThera, an American medical device company headquartered in the United States

4.Cardiologs, headquartered in France, is acquired by Philips, a French developer of ECG analysis systems.

5. The optometrist optometry center was acquired by Sima Ophthalmology, a visual optometry service provider.

6.Autolus has received a strategic investment of US $250 million, invested by Blackstone Group Inc, and the amount of financing this round ranks in the top 10% of all strategic investments this year. Autolus, headquartered in the UK, is a UK provider of cell therapy services

7.Gyroscope Therapeutics received a strategic investment of US $60 million, invested by Sanofi, and the current round of financing ranks in the top 20% of all strategic investments this year. Gyroscope Therapeutics, headquartered in the United Kingdom, is a British ophthalmic disease treatment service provider.

8.PierianDx received US $47.5 million in strategic investment from OrbiMed, SJF Ventures, Catalyst Health Ventures, ATW Partners, Research Triangle Institute and Inova Health Systems. The current round of financing ranks in the top 20% of all strategic investments this year. PierianDx, headquartered in the United States, is an American provider of clinical genomics solutions

9.B-Secur has received US $11.87 million in strategic investment from Bank of Ireland and First Capital Ventures, and the current round of financing ranks in the top 50% of all strategic investments this year. B-Secur, headquartered in the UK, is a UK health monitoring platform

10.HealthSnap received US $5 million in strategic investment from MacDonald Ventures, Florida Funders, OPKO Health, Hard Facts, Wmur5 Group and 6nine26. The company is headquartered in the United States and is an American chronic disease management service provider.

11.MyLife Technologies received a strategic investment of US $4 million from Fare Capital and SAL Beheer. The company is headquartered in the Netherlands and is a provider of vaccination technology in the Netherlands.

12.Antegenes, headquartered in Estonia, is a new Estonian genetic testing service with a strategic investment of US $570000.

13.Biond Biologics completed $15 million in round C financing with investors Harel, Deep Insight and Heritage Group. The company is headquartered in Israel and is an Israeli immunotherapy developer.

14.Arbor Biotechnologies completed $215 million in round B financing, which ranks among the top 5 per cent of all round B financing this year. Arbor Biotechnologies is a gene editing therapy developer.

15.Acrivon has completed round B financing of US $100m, with investors such as Surveyor Capital, Chione, HBM Healthcare Investments AG, Pureos Bioventures, Marshall Wace, Perceptive Advisors, HealthCor Partners, RA Capital Management, Sands Capital Ventures and Wellington. The current round ranks in the top 10% of all round B financing this year. Acrivon, headquartered in the United States, is an American oncology treatment service provider.

16.Infinitus Systems completed US $30 million in round B financing, with Alphabet Inc-CL C Venture Capital, KPCB and Coatue as investors. The current round ranks in the top 50% of all round B financing this year. Infinitus Systems, headquartered in the United States, is an American medical voice robot developer.

17.GeneCentric Therapeutics completed $7.5 million in round B financing with investors Hatteras Venture Partners, IAG Capital Partners, LabCorp, Alexandria Venture Investments (AVI), a US-based cancer drug developer and distributor.

18.Microport NeuroTech completed US $150 million in round A financing, with BVF, HHF Capital and China International Capital Corporation as investors. The current round ranks among the top 5 per cent of all round A financing this year. Headquartered in the Cayman Islands, Microport NeuroTech is a research and development manufacturer of neurovascular diseases and medical devices.

19.GlycoEra completed US $49 million in round A financing, with Sofinnova Partners, 5AM Ventures, Roche Venture Fund and LimmaTech Biologics as investors. The current round ranks in the top 10% of all round A financing this year. GlycoEra, headquartered in Switzerland, is a research and development company of new biological agents in Switzerland.

20.Nitrase Therapeutics completed US $45 million in round A financing, with investors Sofinnova Partners, Bristol-Myers Squibb, AbbVie Biotech Ventures, Mission Bay Capital and Alexandria Venture Investments (AVI). The current round ranks in the top 10% of all round A financing this year. Nitrase Therapeutics is a developer and distributor of drugs for Parkinson's disease.

21.DeepCure completed US $40 million in round A financing, with TLV Partners, Sapir Venture Partners, Benon Group and Morningside Ventures as investors. The current round ranks in the top 10% of all round A financing this year. DeepCure, headquartered in the United States, is an American AI drug developer.

22.Mosaic Wellness completed US $24 million in round A financing, with Matrix Partners, Sequoia Capital India and Elevation Capital as investors. The current round ranks among the top 20 per cent of all round A financing this year. Mosaic Wellness, headquartered in India, is an Indian health care product R & D manufacturer.

23.Signos completed US $13 million in round A financing, with GV as the investor, and the current round ranks in the top 50% of all round A financing this year. Signos, headquartered in the United States, is an American weight management service provider

24.BioSapien has completed a $2.056 million Pre-A round of financing with investors JPIN Venture Catalysts, Cedas Foundation, Side Door Ventures, SOSV, George and Saul, Hikma Ventures, Microventures and Infinite Capital. The company is headquartered in the United States and is a research and development company for cancer drugs.

25.Orthogon Therapeutics completed a $8 million angel round, which ranks in the top 10% of all angel rounds this year. Orthogon Therapeutics is a company that develops antiviral and anti-infective drugs.

26.Asgard Therapeutics completed $6.96 million in seed round financing, funded by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, which ranks in the top 20 per cent of all seed round financing this year. Asgard Therapeutics, headquartered in Sweden, is a Swedish biotechnology company

27.Lindus Health completed US $5 million in seed round financing, with investors such as Hambro Perks, CalmStorm Venture, Presight Capital, individual investors, Amino Collective, Seedcamp and Firstminute Capital. The current round ranks in the top 20% of all seed round financing this year. Lindus Health, headquartered in the United Kingdom, is a British clinical trial service provider.

28.Videra Health completed US $3 million in seed round financing, with OATV, individual investors, Rose Park and Peterson Ventures as investors. The current round ranks in the top 50% of all seed round financing this year. Videra Health, headquartered in the United States, is an American health care service.

29.Acendian completed the seed round financing with investor. Small Business Administration, a US-based drug manufacturer and purchaser.

As of November 14, 2021, a total of 2105 investment and financing events have taken place in the global health care sector this year, with a total financing amount of about 945.448 billion yuan. A total of 1092 investment and financing events occurred in the domestic medical and health field this year, with a total financing amount of about 253.415 billion yuan.

注：

1. The field of health care refers to the health care industry in the 100 million euro data industry classification.

two。 According to the above-mentioned statistics of financing amount, fuzzy finance and undisclosed amount have been converted into estimated values in accordance with certain rules, and uniformly converted into RMB.

To review the investment and financing in health care from November 1 to November 7, please click on the weekly report on investment and financing in health care (November 1-November 7): clover biopharmaceuticals listed

Euro data is committed to providing useful industry insight tools and effective business decision-making tools for organizations that can lead the development of technology and industry. For more detailed investment and financing data in more areas, you are welcome to visit Euro data.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

医疗健康领域投融资周报（11月8日-11月14日）：沙溪制药被京新药业并购

Weekly report on investment and financing in the field of health care (November 8-November 14): Shaxi Pharmaceutical was acquired by Jingxin Pharmaceutical Co., Ltd.

国内医疗健康领域共有2家企业被并购，25家企业获投，融资总额约49.83亿元。

国外医疗健康领域共有1家企业上市，4家企业被并购，24家企业获投，融资总额约107.51亿元。

In the field of medical and health care in China, a total of 2 enterprises were acquired and 25 enterprises were invested, with a total financing of about 4.983 billion yuan.

In the field of medical and health care in foreign countries, a total of 1 enterprise has been listed, 4 enterprises have been acquired, and 24 enterprises have been invested, with a total financing amount of about 10.751 billion yuan.

Risk Disclaimer

Statement